Frederic Pla - Feb 22, 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Chief Operating Officer
Signature: /s/ Frederic Pla, by Brian McKelligon, as Attorney-in-Fact
Stock symbol: AKYA
Transactions as of: Feb 22, 2024
Transactions value $: -$12,355
Form type: 4
Date filed: 3/1/2024, 09:52 PM
Previous filing: Nov 27, 2023
Next filing: Mar 25, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Award	$0	+35K	+49.61%	$0.00	106K	Feb 22, 2024	Direct	F1, F2
transaction	AKYA	Common Stock	Tax liability	-$12.4K	-2.05K	-1.94%	$6.03	104K	Mar 1, 2024	Direct	F3
holding	AKYA	Common Stock						20K	Feb 22, 2024	By The Pla Family Trust dtd 8/7/14

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Employee Stock Option (Right to Buy)	Award	$0	+70K		$0.00	70K	Feb 22, 2024	Common Stock	70K	$5.35	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest in four (4) equal annual installments beginning on March 1, 2025, and annually thereafter until fully vested.
F2	Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
F3	Represents shares withheld to cover taxes on a restricted stock unit award previously granted February 23, 2023, which vest in four (4) equal annual installments beginning on March 1, 2024, and annually thereafter until fully vested.
F4	The options shall vest as follows: twenty-five percent (25%) shall vest on February 22, 2025 with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025.